Evaluation of clinical efficacy after combinational treatment of esophageal cancer using target artery perfusion of verapamil and chemotherapy

• DOI: 10.21037/tcr.2017.11.01
• Publication Date: 2017-12-28T10:54:32Z
• Authors: Yabei Liu; Liting Qian; Kelong Ma; Tengyue Zhang; Gaofei Fan; Yang Wu; Tian Li; Pingsheng Fan; Zhaoshen Li
• Keywords: 0303 health sciences; 03 medical and health sciences

Background: This study aimed to investigate the clinical efficacy of target artery perfusion verapamil combined with chemotherapy in treating esophageal cancer (EC).Methods: A total 46 patients EC (stage III and IV) were treated via infusion. Two four courses per month treatment administrated. Imaging modalities used staging before after include gastroscopy/endoscopic ultrasonography, computed tomography (CT) 64-detector-row gemstone spectral imaging/3.0-T magnetic resonance imaging (MRI). The beneficial rate survival time also evaluated.Results: Out patients, 2 cases achieved complete remission (CR) 39 partial (PR). There 3 had no change progressive disease. overall effective (CR + PR) was 89.13%. After treatment, dysphagia 42 significantly improved except 5 narrow type. 11 hoarseness caused by recurrent laryngeal nerve paralysis therapy recovered normal voice another 7 completely relieved. Forty-five 1 course radiotherapy, patient operation 4 tumor stage decreased. (91.30%) survived for more than a year, 24 (52.17%) years, 12 (26.09%) years. Patients better Karnofsky performance status (KPS) scores, body weight, positive benefit dosage analgesics, which 91.30% (42/46), 52.17% (24/46), 66.67% (4/6), respectively. No significant complication observed verapamil.Conclusions: Target infusion drug reduced advanced (≥ stages III), quality life, prolonged time. And regained opportunity radical radiotherapy or surgery when